Precision Diabetes, Inc.
Precision Diabetes, Inc., headquartered in Raleigh, North Carolina, is a precision medicine company advancing biomarkers for diabetes and diabetic kidney disease (DKD). The company is the exclusive global supplier of the GlycoMark® test, a validated biomarker of short-term glycemic excursions and SGLT-2 inhibitor adherence and response in clinical studies. Precision Diabetes is also advancing DNlite™, a novel biomarker panel for early DKD detection, risk stratification, and renal outcomes assessment in clinical trials and real-world research.
